FIRST PLACEMENT OF APAS® INDEPENDENCE IN UK LAB

APAS® Independence installed at state-of-the-art Health Services Laboratory, London

Adelaide, Australia, 16 July 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the first APAS® Independence placement into a United Kingdom lab.

Key Points

- **APAS® Independence installed at state-of-the-art Health Services Laboratory, Halo Facility**
- **Halo Facility is a lab partnership which includes the U.K. subsidiary of Sonic Healthcare Limited (ASX.SHL)**
- **3 month clinical evaluation of APAS® Independence with MRSA analysis module underway**
- **Successfully installed instrument and training completed remotely due to COVID-19 restrictions**

An APAS® Independence has been installed and commissioned at the Health Services Laboratory (HSL), a state-of-the-art facility located within the Halo building, part of London's life sciences hub, "Medcity". The laboratory is a clinically led provider of pathology and diagnostic services, with the purpose of delivering innovation and value to healthcare. Set up as a partnership between The Doctors Laboratory (a subsidiary of Sonic Healthcare, ASX: SHL), Royal Free London NHS Foundation Trust and University College London Hospitals NHS Foundation Trust, the laboratory combines academic excellence with industry leading workflow efficiency.

HSL will undergo a clinical evaluation of the APAS® technology to assess the utility of the instrument and its potential for integration as part of their automated culture plate workflow. The APAS® Independence will be installed alongside the lab's existing automation solutions, using the MRSA analysis module to identify negative culture plates as part of their antimicrobial resistance surveillance program. Following initial training, the evaluation is expected to be conducted over a 3-month period.

Installation of the APAS® instrument was completed by the Company's recently appointed Service Provider, oneservice AG (**oneservice**). The Company worked closely with both the oneservice and HSL teams to support the installation and conduct instrument training remotely. The process was completed successfully, with the APAS® Independence fully operational within 2 days, demonstrating the ease with which the APAS® Independence can be installed and commissioned within new labs and this will provide a blueprint to follow for future customer evaluations.

Head of Department, Infection Sciences at HSL, Alan Spratt said:

"We are extremely excited to be the first in the UK to trial the APAS® Independence. The application of assisted intelligence in a high-volume lab like ours has the potential to streamline laboratory workflows bringing benefits to staff, quality, turnaround times and consequentially patient outcomes."

LBT CEO and Managing Director, Brent Barnes said:

"Installation of the first APAS® Independence in the UK represents another step forward in the commercialisation of the technology in Europe. We are delighted to be working with a renowned industry leader, such as HSL, and look forward to supporting them through their evaluation of the technology.

It was particularly pleasing to see the teams work closely together to complete the remote installation of the APAS® instrument. This reflects the simple modular design of the technology and demonstrates how the Company can continue to engage with customers whilst COVID-19 travel restrictions remain in place."

First installation of APAS® Independence in the UK

Health Services Laboratory, London - Subsidiary of Sonic Healthcare Ltd

APAS® Independence at the Health Services Laboratory with oneservice engineer following installation

100% remote installation

oneservice completed onsite installation

Remote training of laboratory staff completed online

APAS® operational within laboratory after 2 days

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	**David Allen / John Granger** Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com